Fexofenadine Brain Exposure and the Influence of Blood-Brain Barrier P-Glycoprotein After Fexofenadine and Terfenadine Administration by Zhao, R. et al.
Fexofenadine Brain Exposure and the Influence of Blood-Brain
Barrier P-Glycoprotein After Fexofenadine
and Terfenadine Administration
Rong Zhao, J. Cory Kalvass, Souzan B. Yanni, Arlene S. Bridges, and Gary M. Pollack
Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina (R.Z., G.M.P.); Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (J.C.K.);
Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina (S.B.Y., A.S.B.)
Received October 14, 2008; accepted December 23, 2008
ABSTRACT:
P-glycoprotein (P-gp) plays an important role in determining net
brain uptake of fexofenadine. Initial in vivo experiments with 24-h
subcutaneous osmotic minipump administration demonstrated that
fexofenadine brain penetration was 48-fold higher in mdr1a(/)
mice than in mdr1a(/) mice. In contrast, the P-gp efflux ratio at the
blood-brain barrier (BBB) for fexofenadine was only 4 using an in
situ brain perfusion technique. Pharmacokinetic modeling based on
the experimental results indicated that the apparent fexofenadine
P-gp efflux ratio is time-dependent due to low passive permeability at
the BBB. Fexofenadine brain penetration after terfenadine adminis-
tration was 25- to 27-fold higher than after fexofenadine adminis-
tration in both mdr1a(/) and mdr1a(/) mice, consistent with
terfenadine metabolism to fexofenadine in murine brain tissue. The
fexofenadine formation rate after terfenadine in situ brain perfusion
was comparable with that in a 2-h brain tissue homogenate in vitro
incubation. The fexofenadine formation rate increased 5-fold during
a 2-h brain tissue homogenate incubation with hydroxyl-terfenadine,
suggesting that the hydroxylation of terfenadine is the rate-limiting
step in fexofenadine formation. Moreover, regional brain metabolism
seems to be an important factor in terfenadine brain disposition and,
consequently, fexofenadine brain exposure. Taken together, these
results indicate that the fexofenadine BBB P-gp efflux ratio has been
underestimated previously due to the lack of complete equilibration
of fexofenadine across the blood-brain interface under typical exper-
imental paradigms.
The blood-brain barrier (BBB) and blood-cerebrospinal fluid bar-
rier (BCSFB) are the major interfaces and barriers between the central
nervous system (CNS) and the peripheral circulation. The BBB and
BCSFB are formed by a continuous layer of brain capillary endothe-
lial cells (BBB) or epithelial cells that line the choroid plexus
(BCSFB). The highly developed tight junctions and expression of
numerous efflux transporters and metabolizing enzymes limit brain
penetration of many endogenous compounds and therapeutic agents
(Begley, 2003; Graff and Pollack, 2004).
Brain penetration can be beneficial or detrimental, depending on the
target site of therapy and the potential for untoward side effects.
Adequate exposure in the brain is essential for the treatment of
cerebral diseases. However, brain exposure would ideally be mini-
mized for compounds intended to treat peripheral disorders. BBB
permeability, a primary determinant of substrate exposure in brain
tissue, is influenced by many physicochemical properties such as
molecular weight, pKa, lipophilicity, polar surface area, and the num-
ber of hydrogen bonds (Brodie et al., 1960; Liu et al., 2004). The
extent of brain exposure, and thus the CNS pharmacologic or toxic
effect, is determined by passive permeability, plasma and brain tissue
binding, uptake or efflux transport activity, cerebrospinal fluid (CSF)
bulk flow, and biotransformation in the CNS (Fenstermacher et al.,
1981; Schinkel et al., 1994; Kalvass and Maurer, 2002; Liu and Chen,
2005; Kalvass et al., 2007a). Accurate prediction of CNS penetration
is difficult because of these complex mechanisms and parameters.
In a recent study, nonspecific protein binding (i.e., capacity-limited
binding to proteins other than the target receptor) in brain tissue and
plasma was first used to predict in vivo CNS drug penetration (Kal-
vass and Maurer, 2002). These predictions were based in part on the
assumption that, when compounds distribute between brain and blood
solely by passive diffusion, the unbound brain and plasma concen-
trations are equal at distribution equilibrium. Under these conditions,
the brain-to-plasma concentration ratio (brain partition coefficient;
Kp,brain) is simply a function of the relative plasma and tissue unbound
fractions Kp,brain  fu,plasma/fu,brain. For many compounds that are
subject to P-glycoprotein (P-gp)-mediated efflux at the BBB, brain
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penetration has been predicted successfully based on this approach as
modified to account for the P-gp-mediated efflux activity (Summer-
field et al., 2006; Kalvass et al., 2007a).
Nonsedating antihistamines represent an interesting class of com-
pounds because the lack of a sedative effect is primarily due to
exclusion from the brain at the blood-brain interface. Fexofenadine,
for example, has been identified as a substrate of P-gp in Caco-2 cells
and MDR1-overexpressing LLC-PK1 cells (Cvetkovic et al., 1999;
Petri et al., 2004). P-gp subsequently was demonstrated to decrease
intestinal absorption and brain exposure of fexofenadine by compar-
ing wild-type mice with mdr1a/1b(/) animals (Tahara et al.,
2005).
The extent of fexofenadine brain penetration in normal rats and
mice is minimal (Mahar Doan et al., 2004; Tahara et al., 2005). In
contrast, terfenadine enters the brain rapidly (Mahar Doan et al., 2004;
Obradovic et al., 2007). Terfenadine is metabolized to hydroxyl-
terfenadine and then to the active metabolite fexofenadine by hepatic
CYP3A4 in human (Ling et al., 1995; Markham and Wagstaff, 1998).
Metabolic enzymes such as cytochrome P450s (P450s) are also ex-
pressed in the human and rodent brain (Strobel et al., 2001; Miksys
and Tyndale, 2002; Meyer et al., 2007). Brain P450s play an impor-
tant role in local metabolism of endogenous compounds and xenobi-
otics, although brain P450s is only approximately 1 to 10% of liver
content and not likely to influence the overall metabolism of the body.
Mouse CYP3A11 and CYP3A13, the counterpart of human CYP3A4,
were responsible for 6-hydroxylation of testosterone in the brain and
were induced by antiepileptic drug phenytoin treatment (Hagemeyer
et al., 2003; Meyer et al., 2006). In the current study, the brain
metabolism of terfenadine to fexofenadine was examined.
Despite the ability to predict brain exposure of many compounds,
the P-gp effect coupled with relative protein binding in blood and
brain tissue can only partially explain the impaired brain penetration
of fexofenadine and cetirizine (Kalvass et al., 2007a), two nonsedating
antihistamines with poor permeability at the BBB. Fexofenadine brain
penetration is 35-fold overestimated based on the plasma-to-brain
unbound fraction ratio assumption; this magnitude of overestimation
cannot be explained by the 3-fold P-gp effect at the BBB that has
been reported (Cvetkovic et al., 1999; Tahara et al., 2005). Efflux
protein(s) other than P-gp that may serve as barrier transport systems
at the blood-brain interface have been proposed (Kalvass et al.,
2007a). However, the functional efficiency and biologic significance
of other BBB efflux transporters remain unclear, and no evidence is
available to suggest an interaction between fexofenadine and other
efflux transporters in brain capillary endothelium. The purpose of this
study, therefore, was to understand the underlying mechanism(s)
governing fexofenadine exposure in brain tissue and to re-examine
P-gp-mediated fexofenadine efflux at the BBB. The central hypothesis
underlying this effort is that, to date, studies have underestimated the
actual BBB P-gp effect on fexofenadine brain uptake.
In the current study, the rate and extent of fexofenadine brain
uptake and P-gp-mediated efflux activity at the BBB was deter-
mined using an in situ brain perfusion technique and subcutaneous
osmotic minipump containing fexofenadine or terfenadine in
mdr1a(/) and mdr1a(/) mice, and the drugs were continu-
ously released over 24 to 168 h. A pharmacokinetic model was
used to simulate the time dependence of the P-gp efflux ratio for
fexofenadine and other compounds that have different passive
permeability at the BBB. In addition, the influence of local me-
tabolism on terfenadine brain disposition and consequent fexofe-
nadine brain exposure was investigated.
Materials and Methods
Adult CF-1 mdr1a(/) mice and their natural mutant mdr1a(/) coun-
terparts (30–40 g, 6–8 weeks of age) were purchased from Charles River
Laboratories, Inc. (Wilmington, MA). All mice were maintained on a 12-h
light/dark cycle with access to water and food ad libitum. All experimental
procedures were performed under full anesthesia induced with ketamine/
xylazine (100/10 mg/kg, i.p.). All procedures were approved by the Institu-
tional Animal Care and Use Committee at the University of North Carolina at
Chapel Hill and were conducted in accordance with Principles with Labora-
tory Animal Care (NIH publication no. 85-23, revised in 1985).
[14C]Diazepam (56.0 mCi/mmol) was purchased from GE Healthcare (Little
Chalfont, Buckinghamshire, UK). [3H]Inulin (180.0 mCi/g) was purchased
from PerkinElmer Life and Analytical Sciences (Waltham, MA). Terfenadine,
fexofenadine hydrochloride, and loperamide were purchased from Sigma-
Aldrich (St. Louis, MO). All of the other chemicals were commercially
available and of reagent grade.
In Situ Mouse Brain Perfusion. The details of the in situ mouse brain
perfusion have been described elsewhere (Dagenais et al., 2000). In brief, mice
were anesthetized with ketamine/xylazine (100/10 mg/kg, i.p.). The perfusion
buffer (Krebs-bicarbonate buffer, with 9 mM D-glucose, pH 7.4) was oxygen-
ated with 95% O2 and 5% CO2 and maintained at 37°C. [
14C]Diazepam and
[3H]inulin were used as blood flow rate and vascular space markers, respec-
tively. Fexofenadine or terfenadine at a final concentration of 2 M was added
to the perfusate. The right common carotid artery was cannulated with PE-10
tubing (Braintree Scientific Inc., Braintree, MA) after ligation of the external
carotid artery. The cardiac ventricles were severed immediately before perfu-
sion at 2.5 ml/min for 60 s via a syringe pump (Harvard Apparatus Inc.,
Holliston, MA). The experiment was terminated by decapitation and the right
cerebral hemisphere was collected. Aliquots of perfusate were collected
through the syringe and tubing for determination of substrate concentrations in
perfusate. The perfusate and brain samples were stored at 20°C until analysis
by high-performance liquid chromatography/tandem mass spectrometry
(HPLC/MS/MS). The radioactive brain samples were digested with 0.7 ml
Solvable (PerkinElmer Life and Analytical Sciences) at 50°C overnight. Five
milliliters of UltimaGold scintillation cocktail (PerkinElmer Life and Analyt-
ical Sciences) was added and vortex-mixed. Total radioactivity (3H and/or 14C)
was determined in a Packard Tri-carb TR 1900 liquid scintillation analyzer
(PerkinElmer Life and Analytical Sciences).
Parameters related to the in situ brain perfusion, i.e., the cerebral vascular












where the amount of substrate in brain Xbrain was corrected for blood vessel
contamination by subtraction of vascular volume or a final 15-s washout with
drug-free saline. The permeability surface product (PS) values were calculated
based on the Crone-Renkin equation (Takasato et al., 1984):
PS  Fpf  ln1  ClupFpf.
Fpf is the perfusion flow rate measured using [
14C]diazepam as the flow rate
marker.
Mathematical Modeling and Simulations. The time to equilibrium of
brain penetration is dependent on the passive permeability, brain unbound
fraction, and BBB P-gp-mediated efflux (Liu et al., 2005; Kalvass et al.,
2007b). The time course of P-gp efflux ratio after continuous infusion was
simulated based on a similar model structure with additional P-gp-mediated
efflux activity. As the structure shows in Fig. 1, the model contains one central
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(blood) compartment and one brain compartment; Vc and Vbr are the physio-
logic blood and brain volumes, respectively. Cld represents the passive per-
meability between blood and brain compartments, Cleff is the P-gp-mediated
efflux clearance, Cl is the systemic clearance, and fu,p and fu,br are plasma and
brain unbound fraction, respectively. Modeling was based in part on the
assumption that only unbound drug is able to cross the BBB. The passive
permeability Cld for fexofenadine is very low relative to the blood flow rate
and, therefore, was assumed to be equal to the permeability coefficient PS
determined by the in situ brain perfusion technique. Numerical values for these
parameters were assigned as follows: Vp  49 ml/kg and Vbr  17 ml/kg
(Brown et al., 1997); Cl  30 ml/min/kg (Tahara et al., 2005); fu,p  0.35 and
fu,br  0.077 (Kalvass et al., 2007a). The infusion rate k0 was set to a value of
1 (unit dose). Fexofenadine PS  1.32 ml/min/100 g brain based on the in situ
brain perfusion data. Three pairs of Cld and Cleff were assigned: Cld1  0.022,
Cld2  0.22, Cld3  2.22 ml/min/kg; the corresponding Cleff1  0.54; Cleff2 
5.39, Cleff3  53.90 ml/min/kg for P-gp-competent mice assuming a steady-
state P-gp efflux ratio of 25. Cleff  0 for all P-gp-deficient mice. The P-gp
efflux ratio was calculated as the ratio of brain partition coefficient in P-gp-









 Cld  C  fu,p  Cld  Cleff x Cbr  fu,br
where C and Cbr are the total plasma and brain concentrations, respectively.
In Vivo Osmotic Minipump Studies. CF-1 mice (n  3 per group) were
anesthetized with ketamine/xylazine (100/10 mg/kg, i.p.). An Alzet osmotic
minipump (release rate 1 l/h over 1 week; Alza, Palo Alto, CA) was selected.
Initial experiments were directed at determining fexofenadine brain penetra-
tion and P-gp efflux ratio after fexofenadine and terfenadine administration. To
produce similar plasma concentrations of fexofenadine for comparison, pumps
were filled with fexofenadine hydrochloride (80 g/pump) or terfenadine (900
g/pump) dissolved in 50% dimethyl sulfoxide (200 l/pump) and placed
subcutaneously in the back of mdr1a(/) and mdr1a(/) mice. The
experiment was terminated by decapitation 24 h after implantation. Additional
experiments were performed to study the time course of fexofenadine P-gp
efflux ratio at the BBB. To accomplish this goal, additional groups of
mdr1a(/) and mdr1a(/) mice received fexofenadine hydrochloride (872
g/pump) to produce plasma concentrations similar to those reported by
Tahara et al. (2005). The mice were sacrificed at 24, 72, and 168 h postim-
plantation. Trunk blood was collected in heparinized 1.5-ml microcentrifuge
tubes, and plasma was harvested after centrifugation at 3000 rpm for 5 min.
The plasma and brain samples were stored at 20°C until analysis by HPLC/
MS/MS. The contribution of residual blood in the brain tissue to the brain
partition coefficient was corrected by subtracting 1.8% from the calculated
brain-to-plasma concentration ratio (Brown et al., 1997; Dagenais et al., 2000).
Mouse Brain Metabolism. Terfenadine brain metabolism was determined
under two different experimental conditions. First, mdr1a(/) and
mdr1a(/) mouse brain hemispheres were perfused with 2 M terfenadine
for 1 min (n  3, with a procedure identical to that described under In situ
Mouse Brain Perfusion). The concentrations of fexofenadine formed in the
perfused brain hemisphere were determined by HPLC/MS/MS. Second, fresh
mdr1a(/) mouse brains were harvested, washed with 0.15 M KCl, and
homogenized in two volumes of phosphate buffer (pH 7.4, 1.15% KCl).
Terfenadine or hydroxyl-terfenadine at a final concentration of 200 nM was
incubated with brain homogenate (10 mg/ml) in the presence of potassium
phosphate buffer (0.1 M, pH 7.4) and magnesium chloride (5 mM). The
reaction was initiated by addition of freshly prepared NADPH (2 mM) (Ling
et al., 1995; Holleran et al., 2004). After 2-h incubation at 37°C in a shaking
water bath, the reaction was terminated by addition of ice-cold methanol to
precipitate protein. The samples were centrifuged at 10,000g for 10 min. The
supernatant was transferred to a fresh tube and evaporated under a stream of
dry nitrogen. The residue was reconstituted with 50% methanol in water, and
an internal standard was added. The formation of fexofenadine from terfena-
dine or hydroxyl-terfenadine was determined by HPLC/MS/MS.
Sample Preparation and Quantitation. The brain tissue was homogenized
with addition of two volumes of distilled water after brief probe sonication.
The perfusate was diluted with two volumes of methanol. A 25-l aliquot of
plasma or brain homogenate was transferred to an HPLC vial, and protein was
precipitated with 100 l of methanol containing internal standard (10 ng/ml
loperamide) followed by a 25-l aliquot of dimethyl sulfoxide. The sample
was vortex-mixed and centrifuged. Standard solutions ranging from 0.5 to
5000 nM were prepared in a similar manner. In brief, 25 l of blank plasma
or brain homogenate, 100 l of methanol containing internal standard, and 25
l of serially diluted standard solution were mixed and centrifuged. The
supernatant was analyzed by HPLC-tandem mass spectrometry (API 4000
triple quadrupole with TurboIonSpray interface; Applied Biosystems/MDS
Sciex, Concord, ON, Canada). Three microliters of sample solutions were
injected via an autosampler (Leap, Carrboro, NC). Fexofenadine, terfenadine,
terfenadine-OH, and the internal standard loperamide were eluted from an
Aquasil C18 column (2.1  50 mm, dp  5 m; Thermo Fisher Scientific,
Waltham, MA) using a mobile phase gradient [A, 0.1% formic acid in water;
B, 0.1% formic acid in methanol; 0–0.70-min hold at 0% B, 0.70–3.12-min
linear gradient to 90% B, 3.12–4.10-min hold at 90% B, 4.10–4.20-min linear
gradient to 0% B, 4.20–4.90-min hold at 0% B; solvent delivery system
(Shimadzu, Kyoto, Japan); flow rate  0.75 ml/min; 0.8–4 min directed to
mass spectrometer] and were detected in positive-ion mode using multiple
reaction monitoring: fexofenadine: 502.43466.4 m/z, terfenadine, 472.33
436.5 m/z; terfenadine-OH, 488.33452.5 m/z; loperamide, 477.43266.0 m/z.
All analytes were quantified with standard curves in the linear range of the
relationship between detector response and analyte concentration prepared in
the appropriate matrix. The lower limit of detection was 0.5 ng/ml; inter- and
intraday coefficients of variations were 	15%.
Statistical Analysis. Data are reported as mean 
 S.D. for 3 mice per
condition. A two-tailed Student’s t test, or either a one-way or two-way
analysis of variance (ANOVA), where appropriate, was used to determine the
statistical significance of differences among two or more groups. The level of
significance was corrected for multiple comparisons (e.g., Bonferroni test) or
adjusted for unequal variance when necessary. In all cases, p 	 0.05 was
considered to be statistically significant.
Results
In Situ Mouse Brain Perfusion. [3H]Inulin was used as the brain
capillary space marker to measure the BBB physical integrity.
[14C]Diazepam was perfused as a marker of functional perfusate flow
rate. The vascular volume was 1.69 
 0.10 ml/100 g, and functional
flow rate was 250 
 41 ml/min/100 g brain. P-gp gene deficiency had
no influence on the vascular volume or functional perfusion rate. The
initial brain uptake clearance (Clup, ml/min/100 g brain tissue) of
fexofenadine and terfenadine in mdr1a(/) and mdr1a(/) mice
is shown in Fig. 2. The P-gp efflux ratio, calculated as the ratio of Clup
in mdr1a(/) mice to mdr1a(/) mice, was 4.4 and 1.1 for
fexofenadine and terfenadine, respectively.
Mathematical Modeling and Simulation. Simulations were con-
ducted with three different sets of values for Cld and Cleff (Fig. 3). The
time course of the apparent fexofenadine P-gp efflux ratio was sim-
ulated when Cld was equal to the actual value determined from the in
situ brain perfusion experiment (1  PS). All of the other variables
were physiologic or biologic parameters (i.e., Vc, Vbr, fu,p, and fu,br) or
estimates of fexofenadine pharmacokinetic parameters (i.e., Cl) ob-





FIG. 1. Scheme for the mathematical model used to simulate the P-gp efflux ratio
over time. Parameter definitions are included under Materials and Methods.
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Kalvass et al., 2007a). The simulations predicted that 12 h and 36 h
would be required for fexofenadine to achieve 50 and 90% of the
steady-state P-gp efflux ratio, respectively. When Cld was increased
10-fold, the time to achieve the maximum P-gp efflux ratio shortened.
In contrast, when Cld was 10-fold lower than the actual experimental
value obtained for fexofenadine, the P-gp efflux ratio did not plateau
during the time frame of the simulation.
In Vivo Osmotic Minipump Studies. Fexofenadine brain-to-
plasma concentration ratios at 24 h after administration of either
fexofenadine or terfenadine in mdr1a(/) and mdr1a(/) mice
are displayed in Fig. 4. Steady-state fexofenadine plasma concentra-
tions were 28.5 
 8.3 and 45.5 
 3.1 nM in mdr1a(/) and
mdr1a(/) mice during fexofenadine administration, respectively.
During terfenadine administration, concentrations of terfenadine in
plasma and brain tissue were below the limit of quantitation. How-
ever, plasma concentrations of fexofenadine derived from terfenadine
were identical in mdr1a(/) (7.1 
 2.8 nM) and mdr1a(/)
(7.1 
 1.7 nM) mice. Fexofenadine brain-to-plasma concentration
ratios after 24 h of fexofenadine administration were 0.0056 
 0.010
and 0.27 
 0.08 in mdr1a(/) and mdr1a(/) mice, respectively.
In contrast, the fexofenadine brain-to-plasma concentration ratios
after 24 h of terfenadine administration were 0.14 
 0.03 and 7.44 

2.12 in mdr1a(/) and mdr1a(/) mice, respectively. The fexo-
fenadine brain-to-plasma ratios therefore were 25- and 27-fold
higher in mdr1a(/) and mdr1a(/) mice, respectively, after
terfenadine administration compared with after fexofenadine admin-
istration. The calculated fexofenadine P-gp efflux ratios after fexofe-
nadine and terfenadine administration are 48 and 55, respectively.
Fexofenadine hydrochloride at a dose of 872 g/pump, selected to
produce plasma concentrations (380–480 nM) similar to those in a
previous study by Tahara et al. (2005), was administered in
mdr1a(/) and mdr1a(/) mice for 24, 72, and 168 h. Plasma
concentrations of fexofenadine achieved with this approach were
305 
 74 and 836 
 138 nM in mdr1a(/) and mdr1a(/) mice,
respectively, and did not vary with time during this period. The
brain-to-plasma concentration ratios of fexofenadine during pro-
longed continuous infusion by subcutaneous osmotic minipumps are
shown in Fig. 5. The P-gp efflux ratios were 17, 23, and 25, at 24, 72,
and 168 h, respectively. The calculated P-gp efflux ratio values,
together with the P-gp efflux ratio at 2.5 h from Tahara et al. (2005),
are shown in Fig. 3. These experimentally derived values correspond
closely with the predicted values based on the mathematical
simulation.
Mouse Brain Metabolism. The fexofenadine formation rate in
brain tissue during in situ brain perfusion with 2 M terfenadine for
1 min in mdr1a(/) and mdr1a(/) mice, and after 2-h incubation
of 200 nM terfenadine or hydroxyl-terfenadine with whole brain
tissue homogenate, is displayed in Fig. 6. The fexofenadine formation
rate during 1-min terfenadine brain perfusion was 17.0 
 3.1 and
12.0 
 5.4 nM/min/kg brain tissue in mdr1a(/) and mdr1a(/)
mice, respectively. The fexofenadine formation rate during a 2-h
incubation of whole brain homogenate with terfenadine or hydroxyl-
terfenadine was 12.9 
 3.5 or 74.9 
 11.8 nM/min/kg brain tissue,
respectively.
Discussion
Lipophilicity and ionization at physiologic pH are important deter-
minants of brain penetration (Brodie et al., 1960). Fexofenadine is
ionized at physiologic pH and crosses the BBB to only a minimal
extent. In contrast to preformed fexofenadine, the fexofenadine pro-
drug terfenadine, a very lipophilic molecule, evidenced a brain uptake
that approximated perfusate flow. This very high uptake clearance
was similar between mdr1a(/) and mdr1a(/) mice, even
though terfenadine has been reported to be a P-gp substrate (Mahar
Doan et al., 2004; Obradovic et al., 2007). The lack of a discernible
P-gp effect for this substrate was consistent with the efficient unidi-
rectional uptake of terfenadine during short-term brain perfusion.





















FIG. 2. Initial brain uptake clearance (Clup, ml/min/100 g) for fexofenadine and
terfenadine in mdr1a(/) (solid bar) and mdr1a(/) (open bar) mice. The
mouse brain hemisphere was perfused via the common carotid artery at 2.5 ml/min
for 60 s. Data are presented as mean 
 S.D. (n  3). A Student’s t test was used
to determine the statistical significance of P-gp effect between mdr1a(/) and
mdr1a(/) mice. The asterisk () represents the statistical difference (p 	 0.05)
between mdr1a(/) and mdr1a(/) mice.
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FIG. 3. Simulated P-gp efflux ratios over time for varying Cld and Cleff (—, Cld 
2.24, Cleff  53.90; —–, Cld  0.22, Cleff  5.39; , Cld  0.022, Cleff  0.54;
Cleff  0 for P-gp-deficient mice). The P-gp efflux ratio was calculated as the ratio
of brain-to-plasma concentration ratio in mdr1a(/) mice to mdr1a(/) mice.
The solid circles (F) represent fexofenadine P-gp efflux ratios determined at 24, 72,
and 168 h during subcutaneous osmotic minipump administration. The open circle























FIG. 4. Fexofenadine brain-to-plasma concentration ratio at 24 h in mdr1a(/)
(solid bar) and mdr1a(/) (open bar) mice after subcutaneous osmotic minipump
administration of fexofenadine or terfenadine. Data are presented as mean 
 S.D.
(n  3). Student’s t tests were used to compare brain-to-plasma concentration ratios
between mdr1a(/) and mdr1a(/) mice. The asterisk () represents a statis-
tical difference (p 	 0.05) between mdr1a(/) and mdr1a(/) mice.
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secretion and, thus, in the systemic disposition of this compound.
[14C]Fexofenadine plasma concentrations in mdr1a knockout mice
were 4.6-fold higher than that in wild-type mice after intravenous
administration (Cvetkovic et al., 1999). In the current study, fexofe-
nadine plasma concentrations in mdr1a(/) mice were approxi-
mately 60 to 206% higher than in mdr1a(/) mice. These observa-
tions are in contrast to a previous report by Tahara et al. (2005), which
indicated that plasma concentrations of fexofenadine were similar in
P-gp-competent and P-gp-deficient bile duct-cannulated mice.
P-gp also is involved in fexofenadine penetration of the BBB. The
influence of P-gp on brain uptake of fexofenadine was demonstrated
for the first time with the in situ brain perfusion technique, using the
mdr1a(/) mouse model of P-gp deficiency. The P-gp effect during
short-term brain perfusion (4.4-fold) was modest. In vivo administra-
tion under conditions that produce steady state provides a more
sensitive approach to quantitating the BBB P-gp effect than short-term
brain perfusion when substrate equilibration across the blood-brain
interface is slow. Continuous infusion with a subcutaneous osmotic
minipump provides useful steady-state information from a simple
experimental system. This approach was used in the current study. As
anticipated, the in vivo P-gp efflux ratio exceeded that determined by
the in situ brain perfusion, which has been demonstrated experimen-
tally in the present study and previously (Dagenais et al., 2001). The
present results also are consistent with previous mathematical pre-
dictions based on a simple three-compartment model (representing
plasma, endothelial cell layer, and brain) that showed ER (in vivo
P-gp efflux ratio) must be higher than ERB (in situ P-gp efflux ratio)
for the same substrate and efflux transporter system (Kalvass and
Pollack, 2007).
Fexofenadine brain-to-plasma concentration ratio at 24 h (i.e.,
during continuous minipump administration) was 25- to 27-fold
higher after terfenadine administration than fexofenadine administra-
tion in both mdr1a(/) and mdr1a(/) mice. This difference
might be due to the low permeability of fexofenadine. In the presence
of such a low uptake clearance, a significantly longer period of time
would be required to reach distribution equilibrium across the BBB,
and so the apparent brain-to-plasma ratio at 24 h may be an under-
prediction of the true equilibrium value. Indeed, this situation has
been demonstrated previously by Liu et al. (2005) using a simulation
approach. Alternatively, the precursor of fexofenadine, terfenadine, is
permeable at the BBB. If terfenadine is metabolized in the brain after
crossing the BBB, an increase in fexofenadine brain exposure, relative
to administration of preformed fexofenadine, would be predicted.
To test the first possible mechanism, simulation studies were con-
ducted in parallel with animal experiments. Mathematical modeling
demonstrated that the P-gp efflux ratio must be time-dependent. More-
over, these simulations successfully predicted the P-gp efflux ratios
measured at the selected experimental time points. The interpretation of
the simulation results is both straightforward and logical: because it takes
longer for slowly permeable compounds to equilibrate across the BBB,
the experimentally determined P-gp efflux ratio will also take a longer
time to reach its equilibrium (theoretically maximum) condition. Exper-
imentally, fexofenadine was administered for a prolonged time period up
to 168 h. The present results demonstrate a clear time dependence of
fexofenadine P-gp efflux ratio during this time range of 24 to 168 h. The
determined P-gp efflux ratio values, together with the P-gp efflux ratio of
3.3 at 2.5 h taken from Tahara et al. (2005), were almost superimpos-
able with the predicted values based on the model simulation.
To assess the influence of P-gp on fexofenadine brain exposure when
fexofenadine is formed from terfenadine, versus when fexofenadine is
administered directly, fexofenadine plasma concentrations must be sim-
ilar between the two administration modalities. To achieve similar fexo-
fenadine concentrations from preformed fexofenadine compared with
fexofenadine concentrations after terfenadine administration, fexofena-
dine hydrochloride was administered via osmotic minipump at a contin-
uous rate of 1.5 nM/h. The fexofenadine P-gp efflux ratios determined in
vivo at distribution equilibrium were similar (55 versus 48), regardless of
whether fexofenadine was formed from terfenadine or administered di-
rectly. The P-gp efflux ratio decreased when fexofenadine plasma con-
centration was 10-fold higher (305 nM) in the time course studies,
consistent with at least partial saturation of the transport process.
Based on the impaired brain penetration of fexofenadine in both
mdr1a(/) and mdr1a(/) mice at all time points after fexo-
fenadine administration, the 25- to 27-fold increase of fexofena-
dine brain penetration after terfenadine administration could not be
explained by simply attaining distribution equilibrium more rapidly
with the prodrug. Thus, it was important to address the possibility that
local metabolism of terfenadine to fexofenadine in the brain was
responsible for the observed difference. Terfenadine is metabolized
to hydroxyl-terfenadine then to the carboxylic acid metabolite fexo-
fenadine, by hepatic CYP3A4 in humans. CYP3A11 and 3A13 are the




















FIG. 5. Fexofenadine brain-to-plasma concentration ratio in mdr1a(/) (solid
bar) and mdr1a(/) (open bar) mice at 24, 72, and 168 h after subcutaneous
osmotic minipump administration of fexofenadine. Data are presented as mean 

S.D. (n  3). Two-way ANOVA was used to compare brain-to-plasma concentra-
tion ratios between mdr1a(/) and mdr1a(/) mice, and among the time points,
respectively. The asterisk () represents a statistical difference (p 	 0.05) between
mdr1a(/) and mdr1a(/) mice. There were no differences for fexofenadine


























































FIG. 6. The fexofenadine formation rate in the brain hemisphere after 60-s terfe-
nadine in situ mouse brain perfusion in mdr1a(/) and mdr1a(/) mice, or a
2-h incubation of terfenadine (Terf) or terfenadine-OH (Terf-OH) with whole brain
tissue homogenate. Data are presented as mean 
 S.D. (n  3). One-way ANOVA
statistical analysis corrected for multiple comparisons (Bonferroni test) demon-
strated that fexofenadine formation rate in the brain was significantly higher when
incubated with terfenadine-OH than incubation with terfenadine or 1-min terfena-
dine brain perfusion (, p 	 0.05).
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murine counterparts of human 3A4 and are expressed in the mouse
liver and brain (Hagemeyer et al., 2003; Meyer et al., 2006). After
terfenadine administration, terfenadine plasma and brain concentrations
were below the limit of quantitation, although fexofenadine concentra-
tions in the plasma and brain were substantial. These observations con-
firm efficient metabolism of terfenadine in the mouse. Fexofenadine
plasma concentrations were identical in mdr1a(/) and mdr1a(/)
mice, indicating that the formation rate of fexofenadine from terfenadine
did not differ between mouse strains. Terfenadine seemed to be metab-
olized to fexofenadine in mouse brain during a short (1 min) brain
perfusion, as well as during a 2-h in vitro incubation with brain tissue
homogenate (Fig. 6).
The fexofenadine formation rate in the brain during terfenadine brain
perfusion was comparable between mdr1a(/) and mdr1a(/) mice,
suggesting that the correspondent enzyme(s) activity in brain was not
modulated by P-gp. These novel observations provided supporting evi-
dence, consistent with the pharmacokinetic arguments, that terfenadine
must be metabolized to fexofenadine both systemically and regionally in
the brain. The local metabolism significantly increased fexofenadine
brain exposure compared with what would be expected if fexofenadine
was simply formed from terfenadine systemically.
The enzyme(s) responsible for terfenadine-to-fexofenadine bio-
transformation in murine brain is unknown, although it is reasonable
to speculate that CYP3A11 and/or CYP3A13 may be responsible.
This metabolic situation may have pharmacologic consequences.
Fexofenadine is a nonsedating antihistamine, at least in part because
it does not penetrate the BBB efficiently. In contrast, high-dose
terfenadine administration has been associated with sedative effects
(Mattila and Paakkari, 1999). It is possible that terfenadine itself is the
causative agent for sedation. Alternatively, terfenadine may be inert
but provides sufficient fexofenadine to the brain, via local metabo-
lism, to allow fexofenadine to cause sedation.
Antihistamines represent an interesting pharmacologic class from
the standpoint of BBB permeation and central nervous system respon-
sivity. Fexofenadine and cetirizine are both nonsedating antihista-
mines caused by poor BBB permeability secondary to P-gp-mediated
efflux at the BBB (Polli et al., 2003). Hydroxyzine is sedating, as is
terfenadine at high doses (Mattila and Paakkari, 1999). A comprehen-
sive pharmacokinetic study of cetirizine after intravenous administra-
tion of cetirizine and hydroxyzine has been conducted (Chen et al.,
2003). Re-examination of these published results demonstrated that
the cetirizine P-gp efflux ratio was 4.4 after administration of pre-
formed cetirizine. However, the cetirizine P-gp efflux ratio after admin-
istration of hydroxyzine, the more permeable precursor of cetirizine, was
125 at 240 min. This experimentally determined efflux ratio is remark-
ably similar to the predicted value of 111 based on the unbound fraction
of cetirizine in plasma versus brain and the intrinsic transport activity of
cetirizine by P-gp (Kalvass et al., 2007a). Thus, the overall prediction of
antihistamine brain penetration could be substantially improved by using
accurately determined P-gp efflux ratios (that is, the efflux ratios deter-
mined after complete equilibration across the BBB). Such an approach
would effectively address the two outliers—fexofenadine and cetiriz-
ine—identified in a previous compound set (Kalvass et al., 2007a).
An additional consideration for these compounds is that the ceti-
rizine brain-to-plasma concentration ratio at 240 min was 7-fold
higher after hydroxyzine administration compared with cetirizine ad-
ministration. This situation is analogous to that for the terfenadine-
fexofenadine precursor-metabolite pair as shown in the present series
of experiments. The specific enzyme(s) responsible for hydroxyzine
metabolism are unknown. However, it is conceivable that hy-
droxyzine enters the brain and is subsequently metabolized to cetiriz-
ine, thus increasing cetirizine local exposure after hydroxyzine ad-
ministration. It is clear that additional experimentation would be
required to confirm this speculation.
Based on the current study with the terfenadine/fexofenadine pair,
together with published results for the hydroxyzine/cetirizine pair,
administration of a permeable prodrug seems to provide useful infor-
mation about the true P-gp efflux ratio for a poorly permeable me-
tabolite. For many slow-equilibrating compounds, partitioning
through the BBB is the rate-limiting step in brain uptake. In this
situation, the assumption that simple diffusion of unbound substrate
across the BBB leads to equivalent unbound concentrations in brain
and plasma is violated because distribution equilibrium might not be
achieved within the confines of a given experiment and thus may
result in a lower extent of brain penetration than predicted based on
the equilibrium assumption. Such a situation has been demonstrated
for N[3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]sarcosine, which
failed to reach equilibrium within a 24-h experiment (Liu et al., 2005).
After prodrug administration, a poorly permeable metabolite formed in
the brain (i.e., in capillary endothelial cells, neurons, or glial cells) might
evidence access to the P-gp binding site that is different from access that
could be achieved from the luminal side (i.e., after systemic formation of
the metabolite or direct administration of the preformed compound). The
relative rate of metabolite formation in systemic circulation versus brain
certainly would influence brain exposure, apparent brain-to-blood parti-
tioning, and calculated P-gp efflux ratios. These experimental aspects
warrant further investigation. Taken together, brain exposure is an inte-
grative effect of passive permeability, protein binding in plasma and
brain, interaction with active transporters at the BBB, and, in the special
case of poorly permeable metabolites, systemic and regional brain me-
tabolism. Finally, brain exposure for poorly permeable compounds is
complicated further by CSF bulk flow, which in the mouse is 0.071
ml/min/100 g (Rudick et al., 1982). CSF bulk flow also poses a signifi-
cant influence on the brain exposure of low-permeability compounds (Liu
and Chen, 2005).
In conclusion, the current study investigated fexofenadine brain
penetration and P-gp efflux ratio after fexofenadine and terfenadine
administration. The results demonstrated that P-gp is an important
determinant of fexofenadine efflux at the BBB and, consequently, the
presentation of fexofenadine to brain tissue. Studies to date have
underestimated the actual P-gp efflux ratio of fexofenadine at the
BBB because the P-gp efflux ratio is time-sensitive, and previous
experiments were not sufficiently long to uncover the true efflux ratio.
The present experiments also demonstrated for the first time the
metabolism of terfenadine to fexofenadine in murine brain. The en-
zyme(s) responsible for terfenadine metabolism in the brain require
further investigation. These latter results underscore the fact that
enzymes in the brain or the BBB not only represent a metabolic
barrier for substrate presentation to the brain, but also might activate
some drugs to cause CNS responses (either therapeutic or toxic).
Modulation of brain metabolic enzymes by coadministered drugs
might represent a source of drug-drug interaction.
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